China Resources Double-Crane Pharmaceutical Co., Ltd.SSE: 600062

Announcement on Completion of Phase III Drug Clinical Trial

· Issued by China Resources Double-Crane Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 3 pages · Chinese

Summary by 6ix AI

China Resources Double-Crane Pharmaceutical Co., Ltd. announced the completion of a Phase III clinical trial for its drug, Semaglutide injection, aimed at treating type two diabetes patients. The trial demonstrated clinical equivalence in efficacy and similar pharmacokinetics compared to the original drug from Novo Nordisk, with no significant safety differences observed. The company plans to continue the registration process with the National Medical Products Administration based on the trial results. Investors are advised to be cautious due to potential uncertainties in the drug approval process.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix

Earlier from China Resources Double-Crane Pharmaceutical

Later from China Resources Double-Crane Pharmaceutical

All China Resources Double-Crane Pharmaceutical news releases